NEXGEL Inc. (NXGL), a provider of medical and over-the-counter products, including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, expects revenue growth of over 100% in 2024 and is optimistic about its outlook for 2025.
The company has partnerships with STADA Arzneimittel AG, a European leader in consumer health; Cintas Corp, a provider of corporate identity uniforms, first aid and safety products, and services; and AbbVie Inc. (ABBV), among others.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com